Cytokines and gastric cancer: clinical aspects

1. Chatterjee A., Azevedo-Martins J.M., Stachler M.D. Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights. Onco Targets Ther. 2023;16:675–687. DOI: 10.2147/OTT.S389120. 2. Reyes M.E., Pulgar V., Vivallo C. et al. Epigenetic modulation of cytokine expression in gastric cancer: influence on angiogenesis, metastasis and chemoresistance. Front Immunol. 2024;15:1347530. DOI: 10.3389/fimmu.2024.1347530. 3. Yuan M., Wang L., Huang H. et al. IL-1R2 expression in human gastric cancer and its clinical significance. Biosci Rep. 2021;41(3):BSR20204425. DOI: 10.1042/BSR20204425. 4. Song X., Traub B., Shi J., Kornmann M. Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer. Int J Mol Sci. 2021;22(2):727. DOI: 10.3390/ijms22020727. 5. Wang X., Li J., Liu W. et al. The diagnostic value of interleukin 6 as a biomarker for gastric cancer: A meta-analysis and systematic review. Medicine (Baltimore). 2021;100(47):e27945. DOI: 10.1097/MD.0000000000027945. 6. Li X.N., Peng Y.H., Yue W. et al. A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection. PLoS One. 2022;17(12):e0277908. DOI: 10.1371/journal.pone.0277908. 7. Hou Y., Zhao W., Yang Z., Zhang B. Serum amyloid A (SAA) and Interleukin-6 (IL-6) as the potential biomarkers for gastric cancer. Medicine (Baltimore). 2022;101(43):e31514. DOI: 10.1097/MD.0000000000031514. 8. Liu Z., Tian H., Zhu Z. Application of Circulating Tumor Cells and Interleukin-6 in Preoperative Prediction of Peritoneal Metastasis of Advanced Gastric Cancer. J Inflamm Res. 2023;16:3033–3047. DOI: 10.2147/JIR.S414786. 9. Zhou L., Tang C., Li X., Feng F. IL-6/IL-10 mRNA expression ratio in tumor tissues predicts prognosis in gastric cancer patients without distant metastasis. Sci Rep. 2022;12(1):19427. DOI: 10.1038/s41598-022-24189-3. 10. Li Z., Xu H., Yu J. et al. The Early Diagnostic Value of Serum Interleukin-8 in Esophagogastric Junction Adenocarcinoma. Cancer Control. 2021;28:10732748211004883. DOI: 10.1177/10732748211004883. 11. Lin L., Li L., Ma G. et al. Overexpression of IL-8 and Wnt2 is associated with prognosis of gastric cancer. Folia Histochem Cytobiol. 2022;60(1):66–73. DOI: 10.5603/FHC.a2022.0002. 12. Tang J., Pan R., Xu L. et al. IL10 hypomethylation is associated with the risk of gastric cancer. Oncol Lett. 2021;21(4):241. DOI: 10.3892/ol.2021.12502. 13. Xiong J., Hu H., Kang W. et al. Association of Sarcopenia and Expression of Interleukin-16 in Gastric Cancer Survival. Nutrients. 2022;14(4):838. DOI: 10.3390/nu14040838. 14. Song M., Liang J., Wang L. et al. IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment. Int Immunopharmacol. 2023;123:110757. DOI: 10.1016/j.intimp.2023.110757. 15. Karabulut M., Usul Afsar C., Serimez M., Karabulut S. Serum IL-17 Levels Can Be Diagnostic for Gastric Cancer. J BUON. 2019;24(4):1601–1609. PMID: 31646815. 16. Carneiro B.G.M.C., Petroianu A., Machado J.A.N. et al. Clinical and Immunological Allergy Assessment in Cancer Patients. Sci Rep. 2021;11(1):18110. DOI: 10.1038/s41598-021-97200-y. 17. Rocha G.A., de Melo F.F., Cabral M.M.D.A. et al. Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases. Helicobacter. 2020;25(1):e12667. DOI: 10.1111/hel.12667. 18. Meng D., Dong H., Wang C. et al. Role of interleukin‑32 in cancer progression (Review). Oncol Lett. 2023;27(2):54. DOI: 10.3892/ol.2023.14187. 19. Pisani L.F., Teani I., Vecchi М., Pastorelli L. Interleukin-33: Friend or Foe in Gastrointestinal Tract Cancers? Cells. 2023;12(11):1481. DOI: 10.3390/cells12111481. 20. Gu J.H., Wang X.G., Wang L.Q. et al. Serum level of interleukin-35 as a potential prognostic factor for gastric cancer. Asia Pac J Clin Oncol. 2021;17(1):52–59. DOI: 10.1111/ajco.13403. 21. Li X., Niu N., Sun J. et al. IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1 and IGFBP1. FEBS Open Bio. 2020;10(12):2687–2701. DOI: 10.1002/2211-5463.13005. 22. Zhang R., Jiang M., Huang M. et al. Prognostic value of Interleukin-36s in cancers: A systematic review and meta-analysis. Cytokine. 2023;172:156397. DOI: 10.1016/j.cyto.2023.156397. 23. Han B., Fang T., Zhang Y. et al. Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapy. Front Oncol. 2022;12:920599. DOI: 10.3389/fonc.2022.920599. 24. Han B., Fang T., Wang Y. et al. TGFβ2 is a Prognostic Biomarker for Gastric Cancer and is Associated With Methylation and Immunotherapy Responses. Front Genet. 2022;13:808041. DOI: 10.3389/fgene.2022.808041. 25. Ullah A., Zhao J., Li J. et al. Involvement of CXC chemokines (CXCL1-CXCL17) in gastric cancer: Prognosis and therapeutic molecules. Life Sci. 2024;336:122277. DOI: 10.1016/j.lfs.2023.122277. 26. Liao X., Yang Y., Wang L. et al. CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration. BMC Med Genomics. 2024;17(1):1. DOI: 10.1186/s12920-023-01690-w. 27. Xu D., Liu X., Ke S. et al. CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer. BMC Cancer. 2023;23(1):464. DOI: 10.1186/s12885-023-10882-7. 28. Korbecki J., Bosiacki M., Barczak K. et al. The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers. Cells. 2023;12(10):1406. DOI: 10.3390/cells12101406. 29. Yu B., Xiang L., Peppelenbosch M.P., Fuhler G.M. Overlapping cytokines in H. pylori infection and gastric cancer: A tandem meta-analysis. Front Immunol. 2023;14:1125658. DOI: 10.3389/fimmu.2023.1125658. 30. Nezamzadeh F., Asadyun M., Anbiyaiee A. et al. Association of specific haplotype of tumor necrosis factor-α and interleukin-1β polymorphisms with Helicobacter pylori infection and gastric carcinogenesis. Germs. 2021;11(4):554–561. DOI: 10.18683/germs.2021.1290. 31. Alikhani M., Esmaeili M., Tashakoripour M. et al. Alteration in Serum Levels of Tumor Necrosis Factor Alpha is associated with Histopathologic Progression of Gastric Cancer. Iran Biomed J. 2023;27(1):72–78. DOI: 10.52547/ibj.3847. 32. Della Bella C., D'Elios S., Coletta S. et al. Increased IL-17A Serum Levels and Gastric Th17 Cells in Helicobacter pylori-Infected Patients with Gastric Premalignant Lesions. Cancers (Basel). 2023;15(6):1662. DOI: 10.3390/cancers15061662. 33. Kim H.J., Kim N., Park J.H. et al. Helicobacter pylori Eradication Induced Constant Decrease in Interleukin-1B Expression over More Than 5 Years in Patients with Gastric Cancer and Dysplasia. Gut Liver. 2020;14(6):735–745. DOI: 10.5009/gnl19312. 34. Zhai J., Shen J., Xie G. et al. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Lett. 2019;454:37–43. DOI: 10.1016/j.canlet.2019.04.002. 35. Karalis J.D., Ju M.R., Yoon L.Y. et al. Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer. Ann Surg. 2023;278(6):918–924. DOI: 10.1097/SLA.0000000000005997. 36. Qi Q., Peng Y., Zhu M. et al. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer. Int Immunopharmacol. 2023;114:109553. DOI: 10.1016/j.intimp.2022.109553. 37. Zhao Q., Bi Y., Sun H., Xiao M. Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. Dis Markers. 2021;2021:5526885. DOI: 10.1155/2021/5526885. 38. Fang H., Li R., Gu Y. et al. Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. Oncoimmunology. 2020;9(1):1856468. DOI: 10.1080/2162402X.2020.1856468. 39. Hou Y., Li X., Yang Y. et al. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer. Front Immunol. 2023;14:1274431. DOI: 10.3389/fimmu.2023.1274431. 40. Li S., Li K., Tian F. et al. A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. Front Immunol. 2023;13:1056144. DOI: 10.3389/fimmu.2022.1056144.